Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Cross-talk between myeloid-derived suppressor cells and Mucin1 in breast cancer vaccination: On the verge of a breakthrough
Mahdi Abdoli Shadbad, Khalil Hajiasgharzadeh, Behzad Baradaran
Life Sciences (2020) Vol. 258, pp. 118128-118128
Closed Access | Times Cited: 22

Showing 22 citing articles:

Tumor microenvironment of human breast cancer, and feline mammary carcinoma as a potential study model
Catarina Nascimento, Fernando Ferreira
Biochimica et Biophysica Acta (BBA) - Reviews on Cancer (2021) Vol. 1876, Iss. 1, pp. 188587-188587
Open Access | Times Cited: 56
MDSCs in breast cancer: an important enabler of tumor progression and an emerging therapeutic target
Haoyu Liu, Zhicheng Wang, Zhou Yuntao, et al.
Frontiers in Immunology (2023) Vol. 14
Open Access | Times Cited: 24
A Systematic Review on the Therapeutic Potentiality of PD-L1-Inhibiting MicroRNAs for Triple-Negative Breast Cancer: Toward Single-Cell Sequencing-Guided Biomimetic Delivery
Mahdi Abdoli Shadbad, Sahar Safaei, Oronzo Brunetti, et al.
Genes (2021) Vol. 12, Iss. 8, pp. 1206-1206
Open Access | Times Cited: 50
Regulation of immune responses through CD39 and CD73 in cancer: Novel checkpoints
Elham Baghbani, Saeed Noorolyai, Dariush Shanehbandi, et al.
Life Sciences (2021) Vol. 282, pp. 119826-119826
Closed Access | Times Cited: 43
PD-L1 silencing inhibits triple-negative breast cancer development and upregulates T-cell-induced pro-inflammatory cytokines
Parisa Lotfinejad, Tohid Kazemi, Sahar Safaei, et al.
Biomedicine & Pharmacotherapy (2021) Vol. 138, pp. 111436-111436
Open Access | Times Cited: 39
From Oncogenic Signaling Pathways to Single-Cell Sequencing of Immune Cells: Changing the Landscape of Cancer Immunotherapy
Afshin Derakhshani, Zeinab Rostami, Hossein Safarpour, et al.
Molecules (2021) Vol. 26, Iss. 8, pp. 2278-2278
Open Access | Times Cited: 38
Dendritic cell-based cancer immunotherapy in the era of immune checkpoint inhibitors: From bench to bedside
Farid Ghorbaninezhad, Zahra Asadzadeh, Javad Masoumi, et al.
Life Sciences (2022) Vol. 297, pp. 120466-120466
Closed Access | Times Cited: 26
MicroRNA -383-5p restrains the proliferation and migration of breast cancer cells and promotes apoptosis via inhibition of PD-L1
Shirin Azarbarzin, Mohammad Ali Hosseinpour Feizi, Seyed Mahdi Banan Khojasteh, et al.
Life Sciences (2020) Vol. 267, pp. 118939-118939
Closed Access | Times Cited: 33
From Melanoma Development to RNA-Modified Dendritic Cell Vaccines: Highlighting the Lessons From the Past
Mahdi Abdoli Shadbad, Khalil Hajiasgharzadeh, Afshin Derakhshani, et al.
Frontiers in Immunology (2021) Vol. 12
Open Access | Times Cited: 28
Dual depletion of myeloid-derived suppressor cells and tumor cells with self-assembled gemcitabine-celecoxib nano-twin drug for cancer chemoimmunotherapy
Xiaojie Zhang, Qiangwei Liang, Yongjin Cao, et al.
Journal of Nanobiotechnology (2024) Vol. 22, Iss. 1
Open Access | Times Cited: 4
A Systematic Review to Clarify the Prognostic Values of CD44 and CD44+CD24- Phenotype in Triple-Negative Breast Cancer Patients: Lessons Learned and The Road Ahead
Mahdi Abdoli Shadbad, Negar Hosseinkhani, Zahra Asadzadeh, et al.
Frontiers in Oncology (2021) Vol. 11
Open Access | Times Cited: 26
A Systematic Review on PD-1 Blockade and PD-1 Gene-Editing of CAR-T Cells for Glioma Therapy: From Deciphering to Personalized Medicine
Mahdi Abdoli Shadbad, Nima Hemmat, Vahid Khaze, et al.
Frontiers in Immunology (2022) Vol. 12
Open Access | Times Cited: 16
The cross-talk between tumor-associated macrophages and tumor endothelium: Recent advances in macrophage-based cancer immunotherapy
Ali Baradaran, Zahra Asadzadeh, Nima Hemmat, et al.
Biomedicine & Pharmacotherapy (2021) Vol. 146, pp. 112588-112588
Open Access | Times Cited: 23
The combined restoration of miR-424-5p and miR-142-3p effectively inhibits MCF-7 breast cancer cell line via modulating apoptosis, proliferation, colony formation, cell cycle and autophagy
Narges Dastmalchi, Reza Safaralizadeh, Seyed Mahdi Banan Khojasteh, et al.
Molecular Biology Reports (2022) Vol. 49, Iss. 9, pp. 8325-8335
Closed Access | Times Cited: 11
hsa-miR-34a-5p enhances temozolomide anti-tumoral effects on glioblastoma: in-silico and in-vitro study.
Mahdi Abdoli Shadbad, Amir Baghbanzadeh, Behzad Baradaran
PubMed (2024) Vol. 23, pp. 384-400
Closed Access | Times Cited: 2
Silencing tumor-intrinsic CD73 enhances the chemosensitivity of NSCLC and potentiates the anti-tumoral effects of cisplatin: An in vitro study
Elham Baghbani, Saeed Noorolyai, Shima Rahmani, et al.
Biomedicine & Pharmacotherapy (2021) Vol. 145, pp. 112370-112370
Open Access | Times Cited: 13
A Meta-Analysis of Application of Pd-1/Pd-L1 Inhibitor-Based Immunotherapy in Unresectable Locally Advanced Triple-Negative Breast Cancer
Wei Zhang, Yu‐Jing He, Yuning J. Tang, et al.
Immunotherapy (2023) Vol. 15, Iss. 13, pp. 1073-1088
Open Access | Times Cited: 5
Targeting TGF-β-Mediated SMAD Signaling Pathway via Novel Recombinant Cytotoxin II: A Potent Protein from Naja naja oxiana Venom in Melanoma
Afshin Derakhshani, Nicola Silvestris, Nima Hemmat, et al.
Molecules (2020) Vol. 25, Iss. 21, pp. 5148-5148
Open Access | Times Cited: 14
Inflammatory reflex disruption in COVID‐19
Khalil Hajiasgharzadeh, Mahdi Jafarlou, Behzad Mansoori, et al.
Clinical and Experimental Neuroimmunology (2022) Vol. 13, Iss. 4, pp. 295-301
Open Access | Times Cited: 5
hsa-miR-34a-5p potentiates cytarabine-mediated cell cycle arrest in MDA-MB-231 cells: a novel combination therapy
Saeed Noorolyai, Elham Baghbani, Shima Rahmani, et al.
Pathology - Research and Practice (2022) Vol. 236, pp. 154004-154004
Closed Access | Times Cited: 4
MicroRNA networks in prolactinoma tumorigenesis: a scoping review
Sevil Ghaffarzadeh Rad, Fatemeh Nejadi Orang, Mahdi Abdoli Shadbad
Cancer Cell International (2024) Vol. 24, Iss. 1
Open Access
The combined therapy of miR-383-5p restoration and paclitaxel for treating MDA-MB-231 breast cancer
Narges Dastmalchi, Shirin Azarbarzin, Reza Safaralizadeh, et al.
Medical Oncology (2021) Vol. 39, Iss. 1
Closed Access | Times Cited: 3
Page 1

Scroll to top